Literature DB >> 12899773

[Epidemiologic features, clinical diagnosis and therapy of first cluster of patients with severe acute respiratory syndrome in Beijing area].

Xian-zhi Zhou1, Min Zhao, Fu-sheng Wang, Tian-jun Jiang, Yong-gang Li, Wei-min Nie, Zhi-ping Zhou, Ye Wang, Jing He, Rong Fan, Jing-min Zhao, Xin-wei Zhang.   

Abstract

OBJECTIVE: Investigate the features of outbreak epidemic, clinical disease progression of the first SARS cases in Beijing and evaluate the efficacy of therapeutic regimen.
METHODS: Twenty-nine patients (11 men and 18 women, 20 - 74 years old age range) were diagnosed with infectious SARS and admitted in our hospital from the March 5th to April 14th, 2003 in this study. The data of clinical presentation and disease progression of all the patients including index subject as the infectious SARS resource patient, her family infected members and 21 health care workers were abstracted.
RESULTS: The first SARA outbreak in Beijing was characterized with the cluster feature of resource patient family members and health care providers. The incubation period ranged from 2 to 14 days. All the patients had a fever (temperature > 38 degrees C for over 24 hours) and other manifestations as reported before. Serial chest radiographs showed progressive pathologic air-space disease. Twenty patients showed the severe syndrome with various time ranged from 1 day to 14 days. Two patients died of progressive acute respiratory distress disease. The histologic analysis of one death patient showed diffuse alveolar damage in the two lungs. Twenty-six patients receiving the combined therapy including use of corticosteroid, antiviral ribavirin agents after the onset of symptoms and showed they had an acute self-limited disease course. The oldest patient (74 year old, male) received the healthy convalescent plasma infusion (50 ml) from recovered SARS subject and completely recovered within 21 days, having a shorter disease course.
CONCLUSION: SARS is a kind of new self-limited and acute infectious disease. Early diagnosis, early isolation, early antiviral therapy for patients and efficient prevention for health care providers are urgently recommended. In particular, a combinational therapy of use of antiviral agents, preventive antibacterial antibiotics and pulsed dosage of corticosteroid can efficiently raise the clinical recovery rate and decrease mortality of SARS patients.

Entities:  

Mesh:

Year:  2003        PMID: 12899773

Source DB:  PubMed          Journal:  Zhonghua Yi Xue Za Zhi        ISSN: 0376-2491


  14 in total

1.  Efficacy and safety of convalescent plasma for severe COVID-19 based on evidence in other severe respiratory viral infections: a systematic review and meta-analysis.

Authors:  Niveditha Devasenapathy; Zhikang Ye; Mark Loeb; Fang Fang; Borna Tadayon Najafabadi; Yingqi Xiao; Rachel Couban; Philippe Bégin; Gordon Guyatt
Journal:  CMAJ       Date:  2020-05-22       Impact factor: 8.262

2.  B-cell responses in patients who have recovered from severe acute respiratory syndrome target a dominant site in the S2 domain of the surface spike glycoprotein.

Authors:  Xiaofen Zhong; Huanghao Yang; Zu-Feng Guo; Wan-Yee Fion Sin; Wei Chen; Junjie Xu; Ling Fu; Jie Wu; Chun-Kit Gannon Mak; Chak-Sum Samuel Cheng; Yanzhen Yang; Shuyong Cao; Tin-Yau Wong; Sik-To Lai; Yong Xie; Zhihong Guo
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

3. 

Authors:  Niveditha Devasenapathy; Zhikang Ye; Mark Loeb; Fang Fang; Borna Tadayon Najafabadi; Yingqi Xiao; Rachel Couban; Philippe Bégin; Gordon Guyatt
Journal:  CMAJ       Date:  2020-11-23       Impact factor: 8.262

4.  A potentially effective treatment for COVID-19: A systematic review and meta-analysis of convalescent plasma therapy in treating severe infectious disease.

Authors:  Mengyao Sun; Yinghui Xu; Hua He; Li Zhang; Xu Wang; Qing Qiu; Chao Sun; Ye Guo; Shi Qiu; Kewei Ma
Journal:  Int J Infect Dis       Date:  2020-07-04       Impact factor: 3.623

5.  Purification of severe acute respiratory syndrome hyperimmune globulins for intravenous injection from convalescent plasma.

Authors:  Zhan Zhang; Yi-Wu Xie; Jiling Hong; Xin Zhang; Sui Yi Kwok; Xiaowu Huang; Sai Wah Wong; Bing-Lou Wong
Journal:  Transfusion       Date:  2005-07       Impact factor: 3.157

Review 6.  Positive aspects, negative aspects and limitations of plasma therapy with special reference to COVID-19.

Authors:  Basavraj Nagoba; Ajay Gavkare; Nawab Jamadar; Sachin Mumbre; Sohan Selkar
Journal:  J Infect Public Health       Date:  2020-09-01       Impact factor: 3.718

7.  Persistent shedding of viable SARS-CoV in urine and stool of SARS patients during the convalescent phase.

Authors:  D Xu; Z Zhang; L Jin; F Chu; Y Mao; H Wang; M Liu; M Wang; L Zhang; G F Gao; F S Wang
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-03       Impact factor: 3.267

Review 8.  Convalescent Plasma: Therapeutic Hope or Hopeless Strategy in the SARS-CoV-2 Pandemic.

Authors:  H Cliff Sullivan; John D Roback
Journal:  Transfus Med Rev       Date:  2020-04-23

9.  Genetic variation of SARS coronavirus in Beijing Hospital.

Authors:  Dongping Xu; Zheng Zhang; Fuliang Chu; Yonggang Li; Lei Jin; Lingxia Zhang; George F Gao; Fu-Sheng Wang
Journal:  Emerg Infect Dis       Date:  2004-05       Impact factor: 6.883

Review 10.  The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis.

Authors:  John Mair-Jenkins; Maria Saavedra-Campos; J Kenneth Baillie; Paul Cleary; Fu-Meng Khaw; Wei Shen Lim; Sophia Makki; Kevin D Rooney; Jonathan S Nguyen-Van-Tam; Charles R Beck
Journal:  J Infect Dis       Date:  2014-07-16       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.